Osteoarthritis
This article was originally published in The Tan Sheet
Executive Summary
Novel blend of fatty acid esters (CMC) "may improve the quality of life in patients with [osteoarthritis]," poster presented at FASEB meeting by R.R. Barathur, ClinCyte, et al., states. Double-blind, placebo-controlled, 60-day study of 100 subjects found that after 30 days subjects taking a CMC capsule daily showed a reduction in the Lequesne's Disease Severity Index, identified by knee pain, stiffness and function. The CMC group also displayed "significant improvements in flat ground walking and traversing up and down stairs"